InvestSMART

Genetic Technologies Limited (ASX: GTG) - Share Price

- Current share price for GTG : $0.039

Genetic Technologies Limited (GTG), an ASX-listed company, is a molecular diagnostics company and a global leader in genomics-based testing in health, wellness, and serious disease through its GeneType and EasyDNA brands. GTG provides cancer prediction testing and assessment tools to assist physicians in improving health outcomes for people worldwide.

GTG General Information +

ASX Code GTG
Website N/A
Industry/Sector Life Sciences Tools & Services
Market Cap ($M) 52
GTG Share Price $0.039
Day High $0.039
Day Low $0.039
Last Close $0.039
GTG Share Price Movement - ( No change )
Prices as at 16:36, 22 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Genetic Technologies Limited (GTG) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Genetic Technologies Limited (GTG) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Genetic Technologies Limited (GTG) price-sensitive announcements

GTG - Trading Halt
Genetic Technologies Limited (GTG) has requested an immediate trading halt of its securiti
Genetic Technologies Limited (GTG)
17 Oct 2024 | 9:38 AM
GTG - Security Class Suspension from Quotation GTGN
The ordinary fully paid deferred shares of Genetic Technologies Limited ('GTG') with the s
Genetic Technologies Limited (GTG)
16 Sep 2024 | 6:06 PM
GTG - Entitlement Offer Results and Closing
Genetic Technologies Limited (GTG) announced the closure of its Entitlement Offer on 9 Sep
Genetic Technologies Limited (GTG)
11 Sep 2024 | 4:45 PM
GTG - GTG invited to join prestigious CancerIQ platform
Genetic Technologies Limited (GTG) has partnered with CancerIQ to integrate its geneType R
Genetic Technologies Limited (GTG)
11 Sep 2024 | 10:07 AM

Genetic Technologies Limited (GTG) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Genetic Technologies Limited (GTG)
ORDINARY FULLY PAID
 Health Care $52 Long Term Suspended Entities 10 Jul 2026 4:24PM $0.039 $0.039 fallen by 0%
Genetic Technologies Limited (GTG)
ORDINARY FULLY PAID
 Health Care $52 Termination of ADR Facility 22 Jun 2026 10:34AM $0.039 $0.039 fallen by 0%
Genetic Technologies Limited (GTG)
ORDINARY FULLY PAID
 Health Care $52 Long Term Suspended Entities 17 Apr 2026 2:52PM $0.039 $0.039 fallen by 0%
Genetic Technologies Limited (GTG)
ORDINARY FULLY PAID
 Health Care $52 Quarterly Activities/Appendix 4C Cash Flow Report Sept 2025 30 Mar 2026 12:44PM $0.039 $0.039 fallen by 0%
Genetic Technologies Limited (GTG)
ORDINARY FULLY PAID
 Health Care $52 Quarterly Activities/Appendix 4C Cash Flow Report June 2025 30 Mar 2026 12:44PM $0.039 $0.039 fallen by 0%
Genetic Technologies Limited (GTG)
ORDINARY FULLY PAID
 Health Care $52 Quarterly Activities/Appendix 4C Cash Flow Report March 2025 30 Mar 2026 12:32PM $0.039 $0.039 fallen by 0%

GTG Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2024A -$10.69 -$8.80 -2.50% 0.00 0.00 0.00% 0.0%
2023A -$9.63 -$9.10 33.20% 0.00 0.00 0.00% 0.0%
2022A -$6.57 -$6.80 -14.00% 0.00 0.00 0.00% 0.0%

GTG Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2022 A 2023 A 2024 A 2022 A 2023 A 2024 A 2022 A 2023 A 2024 A
Genetic Technologies Limited (GTG) $52M -0.0254 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

GTG Directors

Name Position Start Date
Mr Michael Malcolm Walker Executive Chairman, Managing Director 14 May 2025
Mr Campbell Douglas Welch Non-Executive Director 24 Mar 2026
Mr Jeffrey Michael Le Compte Non-Executive Director 24 Mar 2026

Genetic Technologies Limited (GTG) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
6 Mar 2024 RUBINSTEIN, Peter Buy Indirect Shares 617,209 $0.130 $80,315.180
30 Jan 2023 MUCHNICKI, Jerzy (George) Sell Indirect Shares 38,400,000 $0.001 $55,898.880
2 Jun 2020 BURROWS, Nicholas (Nick) Buy Direct Shares 1,670,000 $0.006 $10,020.000

See all changes in directors' interest & trades for Genetic Technologies Limited (GTG) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

GTG Management

Name Position
Carl Stubbings Chief Commercial Officer
Simon Morriss Chief Executive Officer
Kevin Camilleri Chief Executive Officer, EasyDNA
Kathryn Andrews Chief Financial Officer
Priyamvada Sanjay Rasal (Pia) Company Secretary

GTG Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Genetic Technologies Limited (GTG). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
103,434,943 (71.13%) The Bank of New York Mellon Corporation

GTG Calendar of Events

Date Event
19 August 2026 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.